Skip to main content

DIMINUTOS, DISTROFIA MIOTONICA DE INICIO INFANTIL Y DEL ADULTO: EVALUACION DE NUEVOS TRATAMIENTOS Y PATOGENICIDAD A TRAVES DE ANALISIS GENETICO, EPIGENETICO Y DE IMAGEN MOLECULAR

PI18/00713

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2018
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Execution centre INSTITUTO DE INVESTIGACION GERMANS TRIAS I PUJOL (IGTP)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immortalized human myotonic dystrophy type 1 muscle cell lines to address patient heterogeneity

  • Núñez-Manchón, Judith
  • Capó, Júlia
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Juanola, Eduard
  • Pesovic, Jovan
  • Mosqueira-Martín, Laura
  • González-Imaz, Klaudia
  • Maestre-Mora, P.
  • Odria, Renato|||0000-0002-3420-797X
  • Savic-Pavicevic, Dusanka
  • Vallejo-Illarramendi, Ainara
  • Mamchaoui, Kamel
  • Bigot, Anne|||0000-0003-0337-5425
  • Mouly, Vicent
  • Suelves, Mònica|||0000-0001-7095-5804
  • Nogales, Gisela|||0000-0002-7414-212X
Historically, cellular models have been used as a tool to study myotonic dystrophy type 1 (DM1) and the validation of therapies in said pathology. However, there is a need for in vitro models that represent the clinical heterogeneity observed in patients with DM1 that is lacking in classical models. In this study, we immortalized three DM1 muscle lines derived from patients with different DM1 subtypes and clinical backgrounds and characterized them at the genetic, epigenetic, and molecular levels. All three cell lines display DM1 hallmarks, such as the accumulation of RNA foci, MBNL1 sequestration, splicing alterations, and reduced fusion. In addition, alterations in early myogenic markers, myotube diameter and CTCF1 DNA methylation were also found in DM1 cells. Notably, the new lines show a high level of heterogeneity in both the size of the CTG expansion and the aforementioned molecular alterations. Importantly, these immortalized cells also responded to previously tested therapeutics. Altogether, our results show that these three human DM1 cellular models are suitable to study the pathophysiological heterogeneity of DM1 and to test future therapeutic options.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Three-dimensional imaging in myotonic dystrophy type 1

  • Ballester-Lopez, Alfonsina|||0000-0002-8922-1664
  • Núñez-Manchón, Judit|||0000-0001-5154-1454
  • Koehorst, Emma
  • Linares-Pardo, Ian
  • Almendrote, Míriam|||0000-0003-0212-275X
  • Lucente, Giuseppe|||0000-0003-1120-9136
  • Guanyabens Busca, Nicolau|||0000-0002-2074-2744
  • Lopez-Osias, Marta
  • Suárez-Mesa, Adrián
  • Hanick, Shaliza Ann
  • Chojnacki, Jakub|||0000-0002-4457-8096
  • Lucia, Alejandro|||0000-0002-3025-2060
  • Pintos-Morell, Guillem|||0000-0002-9347-2386
  • Coll-Cantí, Jaume|||0000-0001-7128-1186
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Ramos-Fransi, Alba|||0000-0002-4114-4575
  • Nogales, Gisela|||0000-0002-7414-212X
We aimed to determine whether 3D imaging reconstruction allows identifying molecular:clinical associations in myotonic dystrophy type 1 (DM1). We obtained myoblasts from 6 patients with DM1 and 6 controls. We measured cytosine-thymine-guanine (CTG) expansion and detected RNA foci and muscleblind like 1 (MBNL1) through 3D reconstruction. We studied dystrophia myotonica protein kinase (DMPK) expression and splicing alterations of MBNL1, insulin receptor, and sarcoplasmic reticulum Ca(2+)-ATPase 1. Three-dimensional analysis showed that RNA foci (nuclear and/or cytoplasmic) were present in 45%-100% of DM1-derived myoblasts we studied (range: 0-6 foci per cell). RNA foci represented <0.6% of the total myoblast nuclear volume. CTG expansion size was associated with the number of RNA foci per myoblast (r = 0.876 [95% confidence interval 0.222-0.986]) as well as with the number of cytoplasmic RNA foci (r = 0.943 [0.559-0.994]). Although MBNL1 colocalized with RNA foci in all DM1 myoblast cell lines, colocalization only accounted for 1% of total MBNL1 expression, with the absence of DM1 alternative splicing patterns. The number of RNA foci was associated with DMPK expression (r = 0.967 [0.079-0.999]). On the other hand, the number of cytoplasmic RNA foci was correlated with the age at disease onset (r = -0.818 [-0.979 to 0.019]). CTG expansion size modulates RNA foci number in myoblasts derived from patients with DM1. MBNL1 sequestration plays only a minor role in the pathobiology of the disease in these cells. Higher number of cytoplasmic RNA foci is related to an early onset of the disease, a finding that should be corroborated in future studies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

An Overview of Alternative Splicing Defects Implicated in Myotonic Dystrophy Type I

  • López-Martínez, Andrea|||0000-0003-4711-7495
  • Soblechero-Martín, Patricia
  • de-la-Puente-Ovejero, Laura|||0000-0002-0835-7069
  • Nogales, Gisela|||0000-0002-7414-212X
  • Arechavala-Gomeza, Virginia|||0000-0001-7703-3255
Myotonic dystrophy type I (DM1) is the most common form of adult muscular dystrophy, caused by expansion of a CTG triplet repeat in the 3' untranslated region (3'UTR) of the myotonic dystrophy protein kinase (DMPK) gene. The pathological CTG repeats result in protein trapping by expanded transcripts, a decreased DMPK translation and the disruption of the chromatin structure, affecting neighboring genes expression. The muscleblind-like (MBNL) and CUG-BP and ETR-3-like factors (CELF) are two families of tissue-specific regulators of developmentally programmed alternative splicing that act as antagonist regulators of several pre-mRNA targets, including troponin 2 (TNNT2), insulin receptor (INSR), chloride channel 1 (CLCN1) and MBNL2. Sequestration of MBNL proteins and up-regulation of CELF1 are key to DM1 pathology, inducing a spliceopathy that leads to a developmental remodelling of the transcriptome due to an adult-to-foetal splicing switch, which results in the loss of cell function and viability. Moreover, recent studies indicate that additional pathogenic mechanisms may also contribute to disease pathology, including a misregulation of cellular mRNA translation, localization and stability. This review focuses on the cause and effects of MBNL and CELF1 deregulation in DM1, describing the molecular mechanisms underlying alternative splicing misregulation for a deeper understanding of DM1 complexity. To contribute to this analysis, we have prepared a comprehensive list of transcript alterations involved in DM1 pathogenesis, as well as other deregulated mRNA processing pathways implications.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Preliminary Findings on CTG Expansion Determination in Different Tissues from Patients with Myotonic Dystrophy Type 1

  • Ballester-Lopez, Alfonsina|||0000-0002-8922-1664
  • Koehorst, Emma
  • Linares-Pardo, Ian
  • Núñez-Manchón, Judit|||0000-0001-5154-1454
  • Almendrote, Míriam|||0000-0003-0212-275X
  • Lucente, Giuseppe|||0000-0003-1120-9136
  • Arbex, Andrea|||0000-0002-3741-4755
  • Puente-Alonso, Carles
  • Lucia, Alejandro|||0000-0002-3025-2060
  • Monckton, Darren G.|||0000-0002-8298-8264
  • Cumming, Sarah A.|||0000-0002-0201-3660
  • Pintos-Morell, Guillem|||0000-0002-9347-2386
  • Coll-Cantí, Jaume|||0000-0001-7128-1186
  • Ramos-Fransi, Alba|||0000-0002-4114-4575
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Nogales, Gisela|||0000-0002-7414-212X
Myotonic Dystrophy type 1 (DM1) is characterized by a high genetic and clinical variability. Determination of the genetic variability in DM1 might help to determine whether there is an association between CTG (Cytosine-Thymine-Guanine) expansion and the clinical manifestations of this condition. We studied the variability of the CTG expansion (progenitor, mode, and longest allele, respectively, and genetic instability) in three tissues (blood, muscle, and tissue) from eight patients with DM1. We also studied the association of genetic data with the patients' clinical characteristics. Although genetic instability was confirmed in all the tissues that we studied, our results suggest that CTG expansion is larger in muscle and skin cells compared with peripheral blood leukocytes. While keeping in mind that more research is needed in larger cohorts, we have provided preliminary evidence suggesting that the estimated progenitor CTG size in muscle could be potentially used as an indicator of age of disease onset and muscle function impairment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Biomarker Potential of miRNAs in Myotonic Dystrophy Type I

  • Koehorst, Emma
  • Ballester-Lopez, Alfonsina|||0000-0002-8922-1664
  • Arechavala-Gomeza, Virginia|||0000-0001-7703-3255
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Nogales, Gisela|||0000-0002-7414-212X
MicroRNAs (miRNAs) are mostly known for their gene regulation properties, but they also play an important role in intercellular signaling. This means that they can be found in bodily fluids, giving them excellent biomarker potential. Myotonic Dystrophy type I (DM1) is the most frequent autosomal dominant muscle dystrophy in adults, with an estimated prevalence of 1:8000. DM1 symptoms include muscle weakness, myotonia, respiratory failure, cardiac conduction defects, cataracts, and endocrine disturbances. Patients display heterogeneity in both age of onset and disease manifestation. No treatment or cure currently exists for DM1, which shows the necessity for a biomarker that can predict disease progression, providing the opportunity to implement preventative measures before symptoms arise. In the past two decades, extensive research has been conducted in the miRNA expression profiles of DM1 patients and their biomarker potential. Here we review the current state of the field with a tissue-specific focus, given the multi-systemic nature of DM1 and the intracellular signaling role of miRNAs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

An Integrative Analysis of DNA Methylation Pattern in Myotonic Dystrophy Type 1 Samples Reveals a Distinct DNA Methylation Profile between Tissues and a Novel Muscle-Associated Epigenetic Dysregulation

  • Koehorst, Emma
  • Odria, Renato|||0000-0002-3420-797X
  • Capó, Júlia
  • Núñez-Manchón, Judit|||0000-0001-5154-1454
  • Arbex, Andrea|||0000-0002-3741-4755
  • Almendrote, Míriam|||0000-0003-0212-275X
  • Linares-Pardo, Ian
  • Natera de Benito, Daniel
  • Saez, Verónica
  • Nascimento, Andrés
  • Ortez González, Carlos Ignacio|||0000-0001-8187-8103
  • Rubio, Miguel Ángel|||0000-0003-0735-6854
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Alonso Pérez, Jorge|||0000-0001-8866-5186
  • Lucente, Giuseppe|||0000-0003-1120-9136
  • Rodríguez-Palmero, Agustí|||0000-0002-4141-5515
  • Ramos-Fransi, Alba|||0000-0002-4114-4575
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Nogales, Gisela|||0000-0002-7414-212X
  • Suelves Esteban, Mònica|||0000-0001-7095-5804
Myotonic dystrophy type 1 (DM1) is a progressive, non-treatable, multi-systemic disorder. To investigate the contribution of epigenetics to the complexity of DM1, we compared DNA methy-lation profiles of four annotated CpG islands (CpGis) in the DMPK locus and neighbouring genes, in distinct DM1 tissues and derived cells, representing six DM1 subtypes, by bisulphite sequencing. In blood, we found no differences in CpGi 74, 43 and 36 in DNA methylation profile. In contrast, a CTCF1 DNA methylation gradient was found with 100% methylation in congenital cases, 50% in childhood cases and 13% in juvenile cases. CTCF1 methylation correlated to disease severity and CTG expansion size. Notably, 50% of CTCF1 methylated cases showed methylation in the CTCF2 regions. Additionally, methylation was associated with maternal transmission. Interestingly, the evaluation of seven families showed that unmethylated mothers passed on an expansion of the CTG repeat, whereas the methylated mothers transmitted a contraction. The analysis of patient-derived cells showed that DNA methylation profiles were highly preserved, validating their use as faithful DM1 cellular models. Importantly, the comparison of DNA methylation levels of distinct DM1 tissues revealed a novel muscle-specific epigenetic signature with methylation of the CTCF1 region accompanied by demethylation of CpGi 43, a region containing an alternative DMPK promoter, which may decrease the canonical promoter activity. Altogether, our results showed a distinct DNA methylation profile across DM1 tissues and uncovered a novel and dual epigenetic signature in DM1 muscle samples, providing novel insights into the epigenetic changes associated with DM1.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Characterization of RAN Translation and Antisense Transcription in Primary Cell Cultures of Patients with Myotonic Dystrophy Type 1

  • Koehorst, Emma
  • Núñez-Manchón, Judit|||0000-0001-5154-1454
  • Ballester-Lopez, Alfonsina|||0000-0002-8922-1664
  • Almendrote, Míriam|||0000-0003-0212-275X
  • Lucente, Giuseppe|||0000-0003-1120-9136
  • Arbex, Andrea|||0000-0002-3741-4755
  • Chojnacki, Jakub|||0000-0002-4457-8096
  • Vázquez-Manrique, Rafael P.|||0000-0002-1594-0033
  • Gómez-Escribano, Ana Pilar|||0000-0003-4391-5932
  • Pintos-Morell, Guillem|||0000-0002-9347-2386
  • Coll-Cantí, Jaume|||0000-0001-7128-1186
  • Ramos-Fransi, Alba|||0000-0002-4114-4575
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Suelves Esteban, Mònica|||0000-0001-7095-5804
  • Nogales, Gisela|||0000-0002-7414-212X
Myotonic Dystrophy type 1 (DM1) is a muscular dystrophy with a multi-systemic nature. It was one of the first diseases in which repeat associated non-ATG (RAN) translation was described in 2011, but has not been further explored since. In order to enhance our knowledge of RAN translation in DM1, we decided to study the presence of DM1 antisense (DM1-AS) transcripts (the origin of the polyglutamine (polyGln) RAN protein) using RT-PCR and FISH, and that of RAN translation via immunoblotting and immunofluorescence in distinct DM1 primary cell cultures, e.g., myoblasts, skin fibroblasts and lymphoblastoids, from ten patients. DM1-AS transcripts were found in all DM1 cells, with a lower expression in patients compared to controls. Antisense RNA foci were found in the nuclei and cytoplasm of a subset of DM1 cells. The polyGln RAN protein was undetectable in all three cell types with both approaches. Immunoblots revealed a 42 kD polyGln containing protein, which was most likely the TATA-box-binding protein. Immunofluorescence revealed a cytoplasmic aggregate, which co-localized with the Golgi apparatus. Taken together, DM1-AS transcript levels were lower in patients compared to controls and a small portion of the transcripts included the expanded repeat. However, RAN translation was not present in patient-derived DM1 cells, or was in undetectable quantities for the available methods.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Second Wind in McArdle Patients, Fitness Matters

  • Salazar-Martínez, Eduardo
  • Santalla, Alfredo|||0000-0001-9418-0564
  • Valenzuela, Pedro L.
  • Nogales, Gisela|||0000-0002-7414-212X
  • Pinós Figueras, Tomàs|||0000-0002-4379-0917
  • Morán, María|||0000-0001-5408-7189
  • Santos-Lozano, Alejandro
  • Fiuza-Luces, Carmen
  • Lucia, Alejandro|||0000-0002-3025-2060
Background: The "second wind" (SW) phenomenon-commonly referring to both an initial period of marked intolerance to dynamic exercise (e.g., brisk walking) that is not followed by perceived improvement and disappearance of previous tachycardia (i.e., the actual "SW") until 6-10 min has elapsed-is an almost unique feature of McArdle disease that limits adherence to an active lifestyle. In this regard, an increase in the workload eliciting the SW could potentially translate into an improved patients' exercise tolerance in daily life. We aimed to determine whether aerobic fitness and physical activity (PA) levels are correlated with the minimum workload eliciting the SW in McArdle patients-as well as with the corresponding heart rate value. We also compared the SW variables and aerobic fitness indicators in inactive vs. active patients. Methods: Fifty-four McArdle patients (24 women, mean ± SD age 33 ± 12 years) performed 12-min constant-load and maximum ramp-like cycle-ergometer tests for SW detection and aerobic fitness [peak oxygen uptake (VO ) and workload and ventilatory threshold] determination, respectively. They were categorized as physically active/inactive during the prior 6 months (active = reporting ≥150 min/week or ≥75 min/week in moderate or vigorous-intensity aerobic PA, respectively) and were also asked on their self-report of the SW. Results: Both peak and submaximal indicators of aerobic fitness obtained in the ramp tests were significantly correlated with the workload of the SW test, with a particularly strong correlation for the VO and peak workload attained by the patients (both Pearson's coefficients.